Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Up 30.0% in January

Bionano Genomics, Inc. (NASDAQ:BNGO) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 443,900 shares, an increase of 30.0% from the January 15th total of 341,500 shares. Approximately 19.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 188,600 shares, the days-to-cover ratio is currently 2.4 days.

Bionano Genomics Price Performance

Shares of BNGO traded up $0.23 during trading hours on Friday, hitting $5.76. 364,504 shares of the stock were exchanged, compared to its average volume of 286,334. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.99 and a current ratio of 1.43. Bionano Genomics has a 12-month low of $4.75 and a 12-month high of $81.00. The company has a market cap of $11.23 million, a price-to-earnings ratio of -0.04 and a beta of 2.13. The stock’s 50-day moving average price is $10.99 and its two-hundred day moving average price is $18.86.

Institutional Trading of Bionano Genomics

Several large investors have recently made changes to their positions in the company. Carret Asset Management LLC grew its holdings in Bionano Genomics by 89.0% in the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after buying an additional 40,055 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Bionano Genomics in the 3rd quarter valued at $46,000. XTX Topco Ltd purchased a new stake in Bionano Genomics in the 4th quarter valued at $45,000. Renaissance Technologies LLC purchased a new stake in Bionano Genomics in the 4th quarter valued at $46,000. Finally, Jane Street Group LLC purchased a new stake in Bionano Genomics in the 4th quarter valued at $118,000. 11.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH cut Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.